Research programme: transforming growth factor-alpha - Kaleidos

Drug Profile

Research programme: transforming growth factor-alpha - Kaleidos

Alternative Names: TGFα

Latest Information Update: 27 Sep 2006

Price : $50

At a glance

  • Originator National Cancer Institute (USA)
  • Class Antineoplastics; Antiulcers; Antivirals; Growth factors; Transforming growth factors
  • Mechanism of Action Transforming growth factor alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued HIV infections; Parkinson's disease

Most Recent Events

  • 27 Sep 2006 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)
  • 27 Sep 2006 Discontinued - Preclinical for Parkinson's disease in USA (unspecified route)
  • 05 Feb 2003 Preclinical data from a media release have been added to the Viral Infections pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top